A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients

Cancer

Volumn 77, Issue 7, 1996, Pages 1386-1394

  Raad, Issam I ^a   Whimbey, Estella E ^a   Rolston, Kenneth V I ^a   Abi Said, Dima ^a   Hachem, Ray Y ^a   Pandya, Rajendra G ^a   Ghaddar, Habib M ^b   Karl, Cynthia L ^a   Bodey, Gerald P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

aztreonam; fever; imipenem; initial antibiotic therapy; neutropenia

Indexed keywords

AZTREONAM; IMIPENEM; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RASH; SUPERINFECTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZTREONAM; BACTERIAL INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; FEVER; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; IMIPENEM; LEUKOCYTE COUNT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; NEUTROPENIA; NEUTROPHILS; PROSPECTIVE STUDIES; VANCOMYCIN;

EID: 0029988175     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960401)77:7<1386::AID-CNCR25>3.0.CO;2-X     Document Type: Article

References (42)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328-40.
2. Schimpff S, Satterlee W, Young V, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061-5.
3. Schimpff SC. Overview of empiric antibiotic therapy for the febrile neutropenic patient. Rev Infect Dis 1985;7(suppl 4):S734-S40.
4. Bodey GP. Evolution of antibiotic therapy for infection in neutropenic patients: studies at M. D. Anderson Hospital. Rev Infect Dis 1989; 11 (7):1582S-90S.
5. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328(18):1323-32.
6. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb D, Young LS. General guidelines for the evaluation of new antiinfective drugs for the treatment of febrile episodes in neutropenic patients. Clin Infect Dis 1992; 15(suppl):206S-15S.
7. Hughes WT, Armstrong D, Bodey GP, Feld F, Mandell GL, Meyers JD, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161:381-96.
8. Ramphal R, Kramer BS, Rand KH, Weiner RS, Shands JW Jr. Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients. J Antimicrob Chemother 1983; 12(suppl):81-8.
9. Pizzo PA, Hathorn JW, Hiemen J, Brown M, Cotton D, Gress J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315:552-8.
10. Bohver R, Fainstein V, Elting L, Bodey GP. Cefoperazone for the treatment of infections in patients with cancer. Rev Infect Dis 1983; 5(suppl):181S-7S.
11. Bodey GP, Alvarez ME, Jones GP, Rolston KV, Steelhammer L, Fainstein V. Imipenem-Cilastatin as initial therapy for febrile cancer patients. Antimicrob Agents Chemother 1986; 30:211-4.
12. Noorby SR, Vandercam BB. Louie T, Runde V, Norberg B, Anniko M, et al. Imipenem/Cilastatin versus Amikacin plus Piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study. Scand J Infect Dis 1987; 52:65-78.
13. Liang R, Yung R, Chau PY, Chan TK, Lam WK, So SY, et al. Imipenem/cilastatin as initial therapy for febrile neutropenic patients. J Antimicrob Chemother 1988; 22:765-70.
14. Bucaneve G, Menichetti F, Minotti V, Pasticci MB, Toato M, Del Favero A. Ceftriaxone versus imipenem/cilastatin as empirical monotherapy for infections in cancer patients. Chemotherapy 1989; 35(suppl):10-5.
15. Hauer C, Urban C, Slavc I, Gamillscheg A, Lackner H. Imipenem-antibiotic monotherapy in juvenile cancer patients with neutropenia. Pediatr Hematol Oncol 1990; 7:229-41.
16. Liang R, Yung R, Chiu E, Chau P-Y, Chan T-K, Lam W-K, et al. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother 1990; 34(7):1336-41.
17. Rolston KVI, Berkey P, Bodey GP, Anaissie EI, Khardori NM, Joshi JH, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 152:283-91.
18. Matsui K, Masuda N, Takada M, Kusunoki Y, Fukuoka M. A randomized trial comparing imipenem/cilastatin alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer. Jpn J Clin Oncol 1991; 21(6):428-34.
19. Riikonen P. Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer. Pediatr Infect Dis J 1991; 10:918-23.
20. Huijgens PC, Ossenkoppele GJ, Weijers TF, van Loenen AC, Simoons-Smit AM, Wijermans PW, et al. Imipenem-cilastatin for empirical therapy in neutropenic patients with fever: an open study in patients with hematologic malignancies. Eur J Haematol 1991; 46:42-6.
21. Cornelissen JJ, de Graeff A, Verdonck F, Branger T, Rozenberg-Arska M, Verhoef J, et al. Imipenem versus gentamicin combined with either cefuroxime or cephalothin as initial therapy for febrile neutropenic patients. Antimicrob Agents Chemother 1992; 36(4):801-7.
22. Leyland MJ, Bayston KF, Cohen J, Warren R, Newland AC, Bint AJ, et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992; 30:843-54.
23. Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, et al. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13(1):165-76.
24. Jones PG, Rolston KVI, Fainstein V, Elting L, Walters RS, Eodey GP. Aztreonam therapy in neutropenic patients with cancer. Am J Med 1986; 81:243-8.
25. Kelsey SM, Shaw E, Newland AC. Aztreonam plus vancomycin versus gentamicin plus piperacillin as empirical therapy for the treatment of fever in neutropenic patients: a randomized controlled study. J Chemother 1992; 4(2):107-13.
26. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992; 14:1201-7.
27. Kern W, Jurrie E, Schmeiser T. Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases. Infection 1990; 18:138-45.
28. Winston DJ, Dudnick DV, Chapin M, Ho WG, Gale RP, Martin WJ. Coagulase negative staphylcoccal bacteremia in patients receiving immunosupplressive therapy. Arch Intern Med 1983; 143:32-6.
29. Karp JE, Dick JD, Angelopoulos C, Charache P, Green L, Burke PJ, et al. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Am J Med 1986; 81:237-42.
30. Whimbey E, Kiehn TE, Brannon P, Blevins, Armstrong D. Bacteremia and fungemia in patients with neoplastic disease. Am J Med 1987; 82:723-9.
31. Viscoli C, van der Auwera P, Meunier F. Gram-positive infections in granulocytopenic patients: an important issue? J Antimicrob Chemother 1988; 21 (suppl): 149-56.
32. EORTC International Antimicrobial Therapy Cooperative Group. Gram-positive bacteremia in granulocytopenic cancer patients: results of a prospective, randomized therapeutic trial. Eur J Cancer Clin Oncol 1990; 26(5):569-74.
33. Neu HC. Aztreonam activity, pharmacology, and clinical use. Am J Med 1990; 88(suppl 3C):2-6.
34. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991; 115:849-59.
35. Heney D, Lewis IJ, Ghoneim ATM, Chisholm P, Bailey CC. Aztreonam therapy in children with febrile neutropenia: a randomized trial of aztreonam plus flucloxacillin versus piperacillin plus gentamicin. J Antimicrob Chemother 1991; 28:117-29.
36. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993; 71(11):3640-6.
37. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. Morb Mortal Wkly Rep 1993; 42:597-9.
38. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995; 16(2):105-12.
39. Maki DG, Schuma AA. A study of antimicrobial misuse in a university hospital. Am J Med Sci 1978; 275:271-82.
40. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Causes of remission induction failure in acute myelogenous leukemia. Blood 1982; 60:309-15.
41. Elting LS, Bodey GP, Fainstein V. Polymicrobial septicemia in the cancer patient. Medicine 1986; 65:218-25.
42. Adkinson NF. Immunogenicity and cross-allergenicity of aztreonam. Am J Med 1990; 88(suppl 3C):12-5.